Browsing Tıp Fakültesi by Subject "Outcomes"
Now showing items 1-6 of 6
-
Differences in reported outcomes in industry-funded vs nonfunded studies assessing thromboprophylaxis after total joint arthroplasty
(Churchill Livingstone Inc Medical Publishers, 2018)Background: There are numerous studies discussing thromboprophylaxis after total joint arthroplasty (TJA), with varying conclusions. Patient inclusion criteria may be different for each study, which may lead to selection ... -
Editorial: The role of vitamin D in gut health and disease in children
(Frontiers Media SA, 2022)The metabolism of vitamin D relies predominantly upon the synthesis of cholecalciferol (vitamin D3) in the epidermis following exposure to sunlight (specifically ultraviolet B rays) and the subsequent hydroxylation to ... -
Five-year outcome and safety in patients treated with immune checkpoint blockade therapies for urothelial carcinoma: Experience from real-world clinical practice
(CIG Media Group, 2023)This 5-year analysis of real-world data confirms the durable response and long-term survival with ICTs in a broader range of patients with metastatic urothelial carcinoma. After 24 months, PFS and OS curves remained nearly ... -
Mid-term results for unicompartmental knee arthroplasty
(2013)PURPOSE OF THE STUDY The purpose of this study was to evaluate clinical and functional results for a series of patients undergoing unicompartmental knee arthroplasty (UKA) at mid-term follow-up. MATERIAL AND METHODS This ... -
Outcomes of the eighth international conference on pediatric mechanical circulatory support systems and pediatric cardiopulmonary perfusion
(Wiley-Blackwell, 2013)The Eighth International Conference on PediatricMechanical Circulatory Support Systems and Pediat-ric Cardiopulmonary Perfusion was held at the Gal-atasaray University, Istanbul, Turkey, June 13–16,2012 (Fig. 1).Atıf ... -
Response to first-line chemotherapy regimen is associated with efficacy of immune checkpoint blockade therapies in patients with metastatic urothelial carcinoma
(Springer, 2022)Background Atezolizumab (ATZ) has demonstrated antitumor activity in previous studies in patients with metastatic platinum-resistant urothelial carcinoma. However, the response rate of ATZ was modest. Therefore, finding ...